On Sept. 11, the Food and Drug Administration cleared OVA1, a test that helps detect ovarian cancer in women with pelvic masses requiring surgery.
On Sept. 11, the Food and Drug Administration cleared OVA1, a test that helps detect ovarian cancer in women with pelvic masses requiring surgery. OVA1 was developed by Vermillion Inc., headquartered in Fremont, Calif., in conjunction with researchers at Johns Hopkins University in Baltimore.
The FDA reviewed a study of 516 women, including 269 patients who were evaluated by non-gynecologic oncologists, comparing OVA1 results with biopsy results. It was determined that, even if other radiographic and clinical tests have negative results, OVA1 could help identify women who might benefit from referral to a gynecologic oncologist for surgery. OVA1 uses a blood sample to test for levels of five proteins that change because of ovarian cancer.
In the news release, the FDA emphasized that the test is only for women aged 18 years and older who have already been selected for surgery because of pelvic masses, and it should complement-not replace-other tests. According to the agency, if other test results suggest cancer, it is appropriate to refer a patient to an oncologist even if OVA1 results are negative.
For more details on the FDA decision, see http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More